The drug industry trade group wants Congress to back off mandates aimed at improving the diversity of clinical trial participants, even as it supports proposals to move these studies into community settings.
“Policies that would create additional mandates for sponsors would have serious unintended consequences of reinforcing rather than overcoming known barriers to participation for patients,” Lucy Vereshchagina, vice president of science and regulatory advocacy for the Pharmaceutical Research and Manufacturers of America, said in prepared testimony released ahead of Thursday’s House Energy and Commerce health subcommittee hearing.
Several bills among the 22 pieces of legislation on the health panel’s ...